Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serotonin Levels Indicate Prognosis of Urothelial Carcinomas

By Labmedica staff writers
Posted on 08 Jul 2008
Serotonin levels are suitable for prognostic evaluation of urothelial carcinoma in the bladder, adenocarcinoma of the prostate, and renal cell carcinoma. More...
A study conducted in Germany examined the relevance of serum serotonin levels to the prognosis and occurrence of these oncologic conditions.

Serotonin levels were obtained in 109 patients presenting with urothelial carcinoma at the department of urology, University of Erlangen-Nuremberg (Erlangen, Germany), where the study took place. Patients who presented with seminomatous and non-seminomatous testicular tumors also took part in the study. All of these conditions varied in grades and metastases. Serum levels were drawn between 7 and 8 a.m. exclusively in order to avoid circadian changes.

The serotonin levels in urothelial carcinoma were related to tumor stage, life expectancy, and distant metastases. In renal cell carcinoma, serotonin levels were decreased in patients with lymph node and distant metastases; there was no significant correlation with extent of infiltration. In cases of testicular carcinoma, decreased serotonin levels were noted in mixed tumors and in one case of extragonadal seminoma--otherwise there was no correlation observed with stage and grade. In prostate cancer, serotonin levels tended to be related to the extent of growth in size of the prostate and the presence of distant metastases.

The study appeared online in the World Journal of Urology on June 26, 2008.


Related Links:
University of Erlangen-Nuremberg

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.